Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?

Abstract

Young-onset type 2 diabetes (YOD), defined as diabetes diagnosis before age 40, has an aggressive clinical course with premature mortality, in part due to long disease duration and lack of evidence to guide diagnosis and management. Autoimmune type 1 diabetes, maturity-onset diabetes of the young (MODY), and latent autoimmune diabetes in adults (LADA) are subtypes of diabetes in young people, which, however, cannot fully explain their complex clinical course. Similarly, family members carrying the same rare genetic variant of monogenic diabetes can have different presentations and outcomes. Ancestral heterogeneity, ecological transition, inter-ethnic differences in genomic architecture, and variations in living environment, lifestyles, access to care, and timeliness of diagnosis and treatment can influence the age of diagnosis and exposure to these cardiometabolic-renal risk factors. Despite the wealth of literature on genetic associations with diabetes, the familial cosegregation of rare variants and their relevance to YOD remains uncertain. This perspective was motivated by decades of clinical observations and learnings from an ongoing randomized controlled trial that uses biogenetic markers to classify patients with YOD for improving outcomes. Apart from highlighting the need to use family-based studies to improve the precision of diagnosis, we discussed atypical causes for diabetic ketoacidosis and the importance of lifecourse and psychosocial-behavioral factors in patients with YOD. Apart from detailed clinical evaluation, we propose using plasma C peptide, homeostasis model of assessment (HOMA) indexes, autoantibodies, and polygenic risk scores to stratify risk, classify diabetes subtypes, and personalize treatment in YOD. To achieve these goals, we advocate changing the practice environment and team structure to enable physicians to use the insights they learn from patients and their family members to implement precision medicine and improve the outlook of these high-risk individuals.

Keywords

Young-onset type 2 diabetes / YOD / genomic medicine / precision medicine / autoimmunity / type 1 diabetes / monogenic diabetes / MODY / LADA / PRISM / randomized controlled trial

References

[1] SunH,KarurangaS.IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res Clin Pract2022;183:109119

[2] XuY,HeJ.2010 China Noncommunicable Disease Surveillance GroupPrevalence and control of diabetes in Chinese adults.JAMA2013;310:948-59

[3] ChanJCN,WarehamNJ.The lancet commission on diabetes: using data to transform diabetes care and patient lives.Lancet2021;396:2019-82

[4] YeungRO,LukA.Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort.Lancet Diabetes Endocrinol2014;2:935-43

[5] KeC,ShahBR.Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: a population-based observational study.PLoS Med2020;17:e1003316 PMCID:PMC7500681

[6] SeshasaiSR,ThompsonA.Emerging Risk Factors CollaborationDiabetes mellitus, fasting glucose, and risk of cause-specific death.N Engl J Med2011;364:829-41 PMCID:PMC4109980

[7] WuH,YangA.Young age at diabetes diagnosis amplifies the effect of diabetes duration on risk of chronic kidney disease: a prospective cohort study.Diabetologia2021;64:1990-2000

[8] WuH,LauESH.Age- and sex-specific hospital bed-day rates in people with and without type 2 diabetes: a territory-wide population-based cohort study of 1.5 million people in Hong Kong.PLoS Med2023;20:e1004261 PMCID:PMC10403124

[9] KeC,ShahBR.Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study.Ann Intern Med2019;170:145-54

[10] SrinivasanS,ToddJ.ProDiGY ConsortiumThe first genome-wide association study for type 2 diabetes in youth: the progress in diabetes genetics in youth (ProDiGY) consortium.Diabetes2021;70:996-1005 PMCID:PMC7980197

[11] ZeitlerP,PyleL.TODAY Study GroupA clinical trial to maintain glycemic control in youth with type 2 diabetes.N Engl J Med2012;366:2247-56 PMCID:PMC3478667

[12] KeC,LukAO,ChanJCN.Cardiovascular outcomes trials in type 2 diabetes: time to include young adults.Diabetes Obes Metab2020;22:3-5

[13] MaglianoDJ,CarstensenB.Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data.Lancet Diabetes Endocrinol2022;10:112-9

[14] MaglianoDJ,BarrELM.Trends in incidence of total or type 2 diabetes: systematic review.BMJ2019;366:l5003

[15] LukAOY,LauESH.Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study.PLoS Med2020;17:e1003052 PMCID:PMC7032690

[16] WuH,MaRCW.Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study.Diabetologia2020;63:757-66

[17] ChanJCN,LukAOY.From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions.Diabetes Care2019;42:2022-31

[18] LukA,FanB.1829-PUB: precision medicine to redefine insulin secretion and monogenic diabetes randomised controlled trial (PRISM-RCT) in Chinese patients with young-onset diabetes - study design and baseline profile.Diabetes2023;72:1829

[19] PolonskyKS,HirschLJ.Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.N Engl J Med1988;318:1231-9

[20] GerichJE.Control of glycaemia.Baillieres Clin Endocrinol Metab1993;7:551-86

[21] PolonskyKS.The past 200 years in diabetes.N Engl J Med2012;367:1332-40

[22] DefronzoRA.Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.Diabetes2009;58:773-95 PMCID:PMC2661582

[23] McCarthyM.Genetics of type 2 diabetes.Curr Rep Diabetes2006;6:147-54

[24] FuchsbergerC,TeslovichTM.The genetic architecture of type 2 diabetes.Nature2016;536:41-7 PMCID:PMC5034897

[25] SpracklenCN,KimYJ.Identification of type 2 diabetes loci in 433,540 East Asian individuals.Nature2020;582:240-5

[26] OgilvieRF.A quantitative estimation of pancreatic islet tissue.QJM1937;6:287-300

[27] YoonKH,ChoJH.Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea.J Clin Endocrinol Metab2003;88:2300-8

[28] ZhaoHL,TongPC.Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes.Diabetes2003;52:2759-66

[29] HartPA,AndersenDK.Consortium for the Study of Chronic PancreatitisDiabetesand Pancreatic Cancer(CPDPC)Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.Lancet Gastroenterol Hepatol2016;1:226-37 PMCID:PMC5495015

[30] LernmarkA,HofmannC.Islet-cell-surface antibodies in juvenile diabetes mellitus.N Engl J Med1978;299:375-80

[31] GregoryGA,LinklaterSE.International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest GroupGlobal incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.Lancet Diabetes Endocrinol2022;10:741-60

[32] MetcalfeKA,RoweRE.Concordance for type 1 diabetes in identical twins is affected by insulin genotype.Diabetes Care2001;24:838-42

[33] SharpSA,HagopianWA.Clinical and research uses of genetic risk scores in type 1 diabetes.Curr Opin Genet Dev2018;50:96-102 PMCID:PMC6089633

[34] NobleJA.Genetics of the HLA region in the prediction of type 1 diabetes.Curr Diab Rep2011;11:533-42 PMCID:PMC3233362

[35] BarrettJC,ConcannonP.Type 1 diabetes genetics consortiumgenome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.Nat Genet2009;41:703-7 PMCID:PMC2889014

[36] RedondoMJ,SteckAK.Type 1 Diabetes TrialNet Study GroupA Type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk.Diabetes Care2018;41:1887-94

[37] BonifacioE,HippichM.TEDDY Study GroupGenetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children.PLoS Med2018;15:e1002548 PMCID:PMC5882115

[38] Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European randomized control trial group.Diabetes1988;37:1574-82

[39] MullardA.FDA approves anti-CD3 antibody to delay type 1 diabetes onset.Nat Rev Drug Discov2023;22:6-7

[40] HeroldKC,LongSA.Type 1 Diabetes TrialNet Study GroupAn Anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.N Engl J Med2019;381:603-13 PMCID:PMC6776880

[41] RamosEL,ChatenoudL.PROTECT Study InvestigatorsTeplizumab and β-Cell function in newly diagnosed type 1 diabetes.N Engl J Med2023;389:2151-61

[42] Padilla-MartínezF,KwasniewskiM.Systematic review of polygenic risk scores for type 1 and type 2 diabetes.Int J Mol Sci2020;21:1703 PMCID:PMC7084489

[43] SimsEK,OramRA,Evans-MolinaC.100 years of insulin: celebrating the past, present and future of diabetes therapy.Nat Med2021;27:1154-64 PMCID:PMC8802620

[44] RodbardD.Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes.Diabetes Technol Ther2017;19:S25-37 PMCID:PMC5467105

[45] NathanDM,LachinJ.Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med1993;329:977-86

[46] BuzzettiR,MauricioD.Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel.Diabetes2020;69:2037-47 PMCID:PMC7809717

[47] ImagawaA.Two types of fulminant type 1 diabetes mellitus: immune checkpoint inhibitor-related and conventional.J Diabetes Investig2021;12:917-9 PMCID:PMC8169369

[48] BornsteinSR,LudwigB.Consequences of the COVID-19 pandemic for patients with metabolic diseases.Nat Metab2021;3:289-92

[49] AtaA,KırkgözT.Does COVID-19 predispose patients to type 1 diabetes mellitus?.Clin Pediatr Endocrinol2022;31:33-7 PMCID:PMC8713063

[50] LimS,KwonHS.COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nat Rev Endocrinol2021;17:11-30 PMCID:PMC7664589

[51] RothmanKJ.Causation and causal inference in epidemiology.Am J Public Health2005;95 Suppl 1:S144-50

[52] AkturkHK,SarwalA,MuradMH.Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis.Diabet Med2019;36:1075-81 PMCID:PMC6698212

[53] PostowMA,HellmannMD.Immune-related adverse events associated with immune checkpoint blockade.N Engl J Med2018;378:158-68

[54] UgaiT,LeeHY.Is early-onset cancer an emerging global epidemic? Current evidence and future implications..Nat Rev Clin Oncol2022;19:656-73 PMCID:PMC9509459

[55] CollierJL,PaukenKE,SharpeAH.Not-so-opposite ends of the spectrum: CD8⁺ T cell dysfunction across chronic infection, cancer and autoimmunity.Nat Immunol2021;22:809-19 PMCID:PMC9197228

[56] MatthewsDR,ProotP,StumvollM.VERIFY study groupGlycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.Lancet2019;394:1519-29

[57] CheungJTK,WuH.Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: a propensity score-matched cohort study.Diabetes Metab Res Rev2023;40:e3711

[58] LaiteerapongN,GaoY.The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study).Diabetes Care2019;42:416-26

[59] HolmanRR,BethelMA,NeilHA.10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med2008;359:1577-89

[60] NathanDM,BacklundJY.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.N Engl J Med2005;353:2643-53 PMCID:PMC2637991

[61] TurnerR,HortonV.UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group.Lancet1997;350:1288-93

[62] BuzzettiR,MaddaloniE.Adult-onset autoimmune diabetes: current knowledge and implications for management.Nat Rev Endocrinol2017;13:674-86

[63] MediciF,IanariA,LeslieRD.Concordance rate for type II diabetes mellitus in monozygotic twins: actuarial analysis.Diabetologia1999;42:146-50

[64] ZhangJ,XiaoJ.China National Diabetes and Metabolic Disorders Study GroupAssociation between family history risk categories and prevalence of diabetes in Chinese population.PLoS One2015;10:e0117044 PMCID:PMC4321835

[65] LiJK,SoWY.Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus.Diabetes Metab Res Rev2006;22:46-52

[66] ZhangY,ChowE.High risk of conversion to diabetes in first-degree relatives of individuals with young-onset type 2 diabetes: a 12-year follow-up analysis.Diabet Med2017;34:1701-9

[67] BonnefondA,DoriaA.Monogenic diabetes.Nat Rev Dis Primers2023;9:12

[68] TattersallRB.Mild familial diabetes with dominant inheritance.Q J Med1974;43:339-57

[69] FajansSS,PolonskyKS.Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.N Engl J Med2001;345:971-80

[70] FeingoldK. Atypical forms of diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279128/ [Last accessed on 15 Jan 2024].

[71] ChanJC,JiaW.Diabetes in Asia: epidemiology, risk factors, and pathophysiology.JAMA2009;301:2129-40

[72] ToddJN,ZhangH.Monogenic diabetes in youth with presumed type 2 diabetes: results from the progress in diabetes genetics in youth (ProDiGY) collaboration.Diabetes Care2021;44:2312-9 PMCID:PMC8929184

[73] ShieldsBM,HudsonM.UNITED study teamPopulation-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients.Diabetes Care2017;40:1017-25 PMCID:PMC5570522

[74] ChristensenAS,StøyJ.Efficacy and safety of glimepiride with or without linagliptin treatment in patients with hnf1a diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA).Diabetes Care2020;43:2025-33 PMCID:PMC7440905

[75] ThewjitcharoenY,TsoiTF,HimathongkamT.Hypertriglyceridemia as a main feature associated with 17q12 deletion syndrome-related hepatocyte nuclear factor 1β-maturity-onset diabetes of the young.Endocrinol Diabetes Metab Case Rep2022;2022:22-0297 PMCID:PMC9513634

[76] ThewjitcharoenY,KrittiyawongS.Phenotypic and genetic heterogeneity in a thai glucokinase MODY family reveals the complexity of young-onset diabetes.Front Endocrinol2021;12:690343 PMCID:PMC8498575

[77] NgMC,SoWY.Nature or nurture: an insightful illustration from a Chinese family with hepatocyte nuclear factor-1 alpha diabetes (MODY3).Diabetologia2000;43:816-8

[78] MatschinskyFM.Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics.Diabetes2002;51 Suppl 3:S394-404

[79] HattersleyAT.Precision diabetes: learning from monogenic diabetes.Diabetologia2017;60:769-77

[80] YabeD.Type 2 diabetes via β-cell dysfunction in east Asian people.Lancet Diabetes Endocrinol2016;4:2-3

[81] FanY,LauESH.Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes.Diabetes Res Clin Pract2023;205:110954

[82] LópezTinoco C,BaconS.Evaluation of pregnancy outcomes in women with GCK-MODY.Diabet Med2021;38:e14488

[83] DickensLT,SanyouraM,PhilipsonLH.Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry.Acta Diabetol2019;56:405-11 PMCID:PMC6468988

[84] ZhuD,LiuY.Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.Lancet Diabetes Endocrinol2018;6:627-36

[85] ChowE,LimCKP.Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes.Diabetes2023;72:299-308 PMCID:PMC9871194

[86] KheraAV,AragamKG.Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.Nat Genet2018;50:1219-24 PMCID:PMC6128408

[87] WangK,YangA.GCKR and GCK polymorphisms are associated with increased risk of end-stage kidney disease in Chinese patients with type 2 diabetes: the Hong Kong Diabetes Register (1995-2019).Diabetes Res Clin Pract2022;193:110118

[88] WangK,HuangC.Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis.Cardiovasc Diabetol2022;21:192 PMCID:PMC9503210

[89] UranoF.Wolfram syndrome: diagnosis, management, and treatment.Curr Diab Rep2016;16:6 PMCID:PMC4705145

[90] DomenechE,NunesV.Wolfram/DIDMOAD syndrome, a heterogenic and molecularly complex neurodegenerative disease.Pediatr Endocrinol Rev2006;3:249-57

[91] ChanJC,CockramCS.DIDMOAD syndrome in a Chinese male with HLA DR7 DRw12.Postgrad Med J1987;63:1109 PMCID:PMC2428578

[92] RichardsS,BaleS.ACMG Laboratory Quality Assurance CommitteeStandards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med2015;17:405-24 PMCID:PMC4544753

[93] LauYL,ChanYY.Prevalence and genotypes of α- and β-thalassemia carriers in Hong Kong - implications for population screening.N Engl J Med1997;336:1298-301

[94] LaoTT.α-Thalassaemia trait and gestational diabetes mellitus in Hong Kong.Diabetologia2001;44:966-71

[95] Fernández-RealJM,MancoM.Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes.Diabetes Care2015;38:2169-76

[96] BaziA,RostamiD,SafaA.Diabetes mellitus in thalassaemia major patients: a report from the southeast of Iran.J Clin Diagn Res2017;11:BC01-4 PMCID:PMC5483650

[97] HusseinN,KaiJ.Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.Cochrane Database Syst Rev2021;10:CD010849 PMCID:PMC8504980

[98] CousensNE,MetcalfeSA.Carrier screening for beta-thalassaemia: a review of international practice.Eur J Hum Genet2010;18:1077-83 PMCID:PMC2987452

[99] GuyerMS.The human genome project and the future of medicine.Am J Dis Child1993;147:1145-52

[100] PociotF.Type 1 diabetes genome-wide association studies: not to be lost in translation.Clin Transl Immunology2017;6:e162

[101] McCarthyM.Personalized profiles for disease risk must capture all facets of health.Nature2021;597:175-7

[102] MaRC.Genetics of diabetic kidney disease-from the worst of nightmares to the light of dawn?.J Am Soc Nephrol2017;28:389-93 PMCID:PMC5280033

[103] StadlerLKJ.A new drug target for type 2 diabetes.Cell2017;170:12-4

[104] HaraK,JohnsonTA.DIAGRAM consortiumGenome-wide association study identifies three novel loci for type 2 diabetes.Hum Mol Genet2014;23:239-46

[105] UdlerMS,FlorezJC.Genetic risk scores for diabetes diagnosis and precision medicine.Endocr Rev2019;40:1500-20 PMCID:PMC6760294

[106] GuinanK,TremblayJ.Economic evaluation of a new polygenic risk score to predict nephropathy in adult patients with type 2 diabetes.Can J Diabetes2021;45:129-36

[107] TremblayJ,AttaouaR.Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.Diabetologia2021;64:2012-25 PMCID:PMC8382653

[108] NoordamR,SmitRAJ.Stratification of type 2 diabetes by age of diagnosis in the UK biobank reveals subgroup-specific genetic associations and causal risk profiles.Diabetes2021;70:1816-25

[109] HermanW,BrandleM.The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.Ann Intern Med2005;142:323-32 PMCID:PMC2701392

[110] ZhangL,ShenS.China Diabetes Prevention Program Study GroupSafety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.Lancet Diabetes Endocrinol2023;11:567-77

[111] HahnSJ,ChoiYS,KangJ.Prediction of type 2 diabetes using genome-wide polygenic risk score and metabolic profiles: A machine learning analysis of population-based 10-year prospective cohort study.EBioMedicine2022;86:104383 PMCID:PMC9713286

[112] LimLL,ChanJCN.Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.Nat Rev Endocrinol2023;19:151-63

[113] ChoiJG,SkandariMR.First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists : a cost-effectiveness study.Ann Intern Med2022;175:1392-400 PMCID:PMC10155215

[114] KnowlesJW,KhouryMJ.Cascade screening for familial hypercholesterolemia and the use of genetic testing.JAMA2017;318:381-2 PMCID:PMC6166431

[115] ChanJC,OldenburgB.JADE and PEARL Project TeamEffects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial.JAMA Intern Med2014;174:972-81

[116] ChanJC,LukA.JADE Collaborative Study GroupDelivery of integrated diabetes care using logistics and information technology - the Joint Asia Diabetes Evaluation (JADE) program.Diabetes Res Clin Pract2014;106 Suppl 2:S295-304

[117] MaRCW. Implementation of precision genetic approaches for type 1 and 2 diabetes. In: Basu R, editor. Precision medicine in diabetes. Cham: Springer International Publishing; 2022. pp. 111-29.

[118] MaRCW,LimCKP.A randomized clinical trial of genetic testing and personalized risk counselling in patients with type 2 diabetes receiving integrated care -the genetic testing and patient empowerment (GEM) trial.Diabetes Res Clin Pract2022;189:109969

[119] GrantRW,PandiscioJC,NathanDM.The clinical application of genetic testing in type 2 diabetes: a patient and physician survey.Diabetologia2009;52:2299-305 PMCID:PMC3829642

[120] BensellamM,LaybuttDR.Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions.J Endocrinol2018;236:R109-43

[121] HolmanRR.Assessing the potential for α-glucosidase inhibitors in prediabetic states.Diabetes Res Clin Pract1998;40 Suppl:S21-5

[122] WengJ,XuW.Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.Lancet2008;371:1753-60

[123] ChanJCN,MathieuC,MatthewsDR.Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study.Diabetes Obes Metab2021;23:245-51

[124] LukAOY,LimC.Diabetes-related complications and mortality in patients with young-onset latent autoimmune diabetes: a 14-year analysis of the prospective Hong Kong diabetes register.Diabetes Care2019;42:1042-50

[125] FanB,PoonEWM.Differential associations of GAD antibodies (GADA) and C-peptide with insulin initiation, glycemic responses, and severe hypoglycemia in patients diagnosed with type 2 diabetes.Diabetes Care2023;46:1282-91 PMCID:PMC10261876

[126] BergerB,SundkvistG.Random C-peptide in the classification of diabetes.Scand J Clin Lab Invest2000;60:687-93

[127] KahnSE.The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes.Diabetologia2004;46:3-19

[128] FanB,ShiM.Associations of the HOMA2-%B and HOMA2-IR with progression to diabetes and glycaemic deterioration in young and middle-aged Chinese.Diabetes Metab Res Rev2022;38:e3525

[129] AhlqvistE,KäräjämäkiA.Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.Lancet Diabetes Endocrinol2018;6:361-9

[130] LiX,CaoC.Validation of the Swedish Diabetes re-grouping scheme in adult-onset diabetes in China.J Clin Endocrinol Metab2020;105:e3519-28

[131] KeC,ChanJCN,ShahBR.Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations.Nat Rev Endocrinol2022;18:413-32 PMCID:PMC9067000

[132] ChanSP,ChanJCN.Adjusting the use of glucose-lowering agents in the real-world clinical management of people with type 2 diabetes: a narrative review.Diabetes Ther2023;14:823-38 PMCID:PMC10015140

[133] ShieldsBM,AngwinCD.TriMaster Study groupPatient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.Nat Med2023;29:376-83 PMCID:PMC7614216

[134] ChowE,ChungCHL.A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer.Pharmaceuticals2022;15:442 PMCID:PMC9030054

[135] TahraniAA,DelPrato S.Management of type 2 diabetes: new and future developments in treatment.Lancet2011;378:182-97

[136] DennisJM.Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment.Diabetes2020;69:2075-85 PMCID:PMC7506836

[137] KoGT,TongPC.Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus.CMAJ2009;180:919-26 PMCID:PMC2670904

[138] MatthewsD,MohanV.Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes.Diabetes Ther2020;11:2465-76 PMCID:PMC7547931

[139] Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2022.Diabetes Care2022;45:S60-82

[140] LaoTT,LeungWC,TseKY.Maternal hepatitis B infection and gestational diabetes mellitus.J Hepatol2007;47:46-50

[141] MageeMJ,GandhiNR.Increased risk of incident diabetes among individuals with latent tuberculosis infection.Diabetes Care2022;45:880-7 PMCID:PMC9016736

[142] GoldenSH,CarnethonM.Examining a bidirectional association between depressive symptoms and diabetes.JAMA2008;299:2751-9 PMCID:PMC2648841

[143] HarrisML,HureA,LoxtonD.Stress increases the risk of type 2 diabetes onset in women: a 12-year longitudinal study using causal modelling.PLoS One2017;12:e0172126 PMCID:PMC5319684

[144] FisherEB,NanH,OldenburgB.Co-occurrence of diabetes and depression: conceptual considerations for an emerging global health challenge.J Affect Disord2012;142 Suppl:S56-66

[145] PeyrotM,DaviesM.Diabetes attitudes wishes and needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care.Diabetes Res Clin Pract2013;99:174-84

[146] NicolucciA,HoltRI.DAWN2 Study GroupDiabetes attitudes, wishes and needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes.Diabet Med2013;30:767-77

[147] RiazH.Best practice advisories should not replace good clinical acumen.Am J Med2017;130:245-6

[148] ToddJW.The superior clinical acumen of the old physicians, a myth.Lancet1953;1:482-4

[149] FullerJ.The new medical model: a renewed challenge for biomedicine.CMAJ2017;189:E640-1 PMCID:PMC5415394

[150] ChungWK,FlorezJC.Precision Medicine in Diabetes: a consensus report from the American diabetes association (ADA) and the European association for the study of diabetes (EASD).Diabetes Care2020;43:1617-35 PMCID:PMC7305007

[151] XieF,MaRC.Precision medicine in diabetes prevention, classification and management.J Diabetes Investig2018;9:998-1015 PMCID:PMC6123056

[152] ChanJCN,MaRCW,WongR.The complexity of vascular and non-vascular complications of diabetes: the Hong Kong diabetes registry.Curr Cardiovasc Risk Rep2011;5:230-9 PMCID:PMC3085116

[153] HannawaAF,KolyadaA,DonaldsonLJ.The aspects of healthcare quality that are important to health professionals and patients: a qualitative study.Patient Educ Couns2022;105:1561-70

[154] LimLL,KongAPS.Aspects of multicomponent integrated care promote sustained improvement in surrogate clinical outcomes: a systematic review and meta-analysis.Diabetes Care2018;41:1312-20 PMCID:PMC5961399

[155] BackhouseA.Quality improvement into practice.BMJ2020;368:m865 PMCID:PMC7190269

[156] LimLL,OzakiR.Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE program: a retrospective cohort analysis.PLoS Med2020;17:e1003367 PMCID:PMC7531841

[157] GlasgowRE,GaglioB.RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review.Front Public Health2019;7:64 PMCID:PMC6450067